Cargando…
Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience
Lorlatinib is the only targeted therapy approved in Canada to treat patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) whose tumor has progressed despite treatment with second-generation ALK tyrosine kinase inhibitor (TKI), a patient population with high unmet...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377946/ https://www.ncbi.nlm.nih.gov/pubmed/37504341 http://dx.doi.org/10.3390/curroncol30070481 |
_version_ | 1785079643843330048 |
---|---|
author | Rupp, Martin Fanton-Aita, Fiorella Snow, Stephanie Wheatley-Price, Paul Melosky, Barbara Juergens, Rosalyn A. Chu, Quincy Blais, Normand Banerji, Shantanu Ng, Ryan Khoudigian, Shoghag Sharma, Arushi On, Phu Vinh Liu, Geoffrey |
author_facet | Rupp, Martin Fanton-Aita, Fiorella Snow, Stephanie Wheatley-Price, Paul Melosky, Barbara Juergens, Rosalyn A. Chu, Quincy Blais, Normand Banerji, Shantanu Ng, Ryan Khoudigian, Shoghag Sharma, Arushi On, Phu Vinh Liu, Geoffrey |
author_sort | Rupp, Martin |
collection | PubMed |
description | Lorlatinib is the only targeted therapy approved in Canada to treat patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) whose tumor has progressed despite treatment with second-generation ALK tyrosine kinase inhibitor (TKI), a patient population with high unmet need and lack of publicly reimbursed targeted treatments in Canada. We prospectively examined the real-world effectiveness and impact of lorlatinib on quality-of-life in 59 lorlatinib-treated patients, characterized as: median age of 62.0 years; 47.5% were female; 32.2% had central nervous system metastases; 50.8% had 2+ prior ALK TKI lines; and alectinib was the most common ALK TKI (72.9%) administered before lorlatinib, including 44.1% who received first-line alectinib. With a median follow-up of 15.3 months (IQR: 6.2–19.2), median time-to-treatment discontinuation of lorlatinib was 15.3 months (95% CI: 7.9–not reached), with 54.2% (95% CI: 40.8–65.9%) of patients without treatment discontinuation at 12 months. At baseline, the mean health utility score (HUS) was 0.744 (SD: 0.200). At 3 months, patients receiving lorlatinib demonstrated a 0.069 (95% CI: 0.020–0.118; p = 0.007) average HUS increase over baseline; HUS was maintained at 6 and 12 months. Thus, patients with ALK-positive NSCLC post second-generation ALK TKI remained on lorlatinib for a meaningful duration of time while their quality-of-life was preserved. |
format | Online Article Text |
id | pubmed-10377946 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103779462023-07-29 Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience Rupp, Martin Fanton-Aita, Fiorella Snow, Stephanie Wheatley-Price, Paul Melosky, Barbara Juergens, Rosalyn A. Chu, Quincy Blais, Normand Banerji, Shantanu Ng, Ryan Khoudigian, Shoghag Sharma, Arushi On, Phu Vinh Liu, Geoffrey Curr Oncol Article Lorlatinib is the only targeted therapy approved in Canada to treat patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) whose tumor has progressed despite treatment with second-generation ALK tyrosine kinase inhibitor (TKI), a patient population with high unmet need and lack of publicly reimbursed targeted treatments in Canada. We prospectively examined the real-world effectiveness and impact of lorlatinib on quality-of-life in 59 lorlatinib-treated patients, characterized as: median age of 62.0 years; 47.5% were female; 32.2% had central nervous system metastases; 50.8% had 2+ prior ALK TKI lines; and alectinib was the most common ALK TKI (72.9%) administered before lorlatinib, including 44.1% who received first-line alectinib. With a median follow-up of 15.3 months (IQR: 6.2–19.2), median time-to-treatment discontinuation of lorlatinib was 15.3 months (95% CI: 7.9–not reached), with 54.2% (95% CI: 40.8–65.9%) of patients without treatment discontinuation at 12 months. At baseline, the mean health utility score (HUS) was 0.744 (SD: 0.200). At 3 months, patients receiving lorlatinib demonstrated a 0.069 (95% CI: 0.020–0.118; p = 0.007) average HUS increase over baseline; HUS was maintained at 6 and 12 months. Thus, patients with ALK-positive NSCLC post second-generation ALK TKI remained on lorlatinib for a meaningful duration of time while their quality-of-life was preserved. MDPI 2023-07-08 /pmc/articles/PMC10377946/ /pubmed/37504341 http://dx.doi.org/10.3390/curroncol30070481 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Rupp, Martin Fanton-Aita, Fiorella Snow, Stephanie Wheatley-Price, Paul Melosky, Barbara Juergens, Rosalyn A. Chu, Quincy Blais, Normand Banerji, Shantanu Ng, Ryan Khoudigian, Shoghag Sharma, Arushi On, Phu Vinh Liu, Geoffrey Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience |
title | Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience |
title_full | Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience |
title_fullStr | Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience |
title_full_unstemmed | Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience |
title_short | Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience |
title_sort | lorlatinib effectiveness and quality-of-life in patients with alk-positive nsclc who had failed second-generation alk inhibitors: canadian real-world experience |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377946/ https://www.ncbi.nlm.nih.gov/pubmed/37504341 http://dx.doi.org/10.3390/curroncol30070481 |
work_keys_str_mv | AT ruppmartin lorlatinibeffectivenessandqualityoflifeinpatientswithalkpositivensclcwhohadfailedsecondgenerationalkinhibitorscanadianrealworldexperience AT fantonaitafiorella lorlatinibeffectivenessandqualityoflifeinpatientswithalkpositivensclcwhohadfailedsecondgenerationalkinhibitorscanadianrealworldexperience AT snowstephanie lorlatinibeffectivenessandqualityoflifeinpatientswithalkpositivensclcwhohadfailedsecondgenerationalkinhibitorscanadianrealworldexperience AT wheatleypricepaul lorlatinibeffectivenessandqualityoflifeinpatientswithalkpositivensclcwhohadfailedsecondgenerationalkinhibitorscanadianrealworldexperience AT meloskybarbara lorlatinibeffectivenessandqualityoflifeinpatientswithalkpositivensclcwhohadfailedsecondgenerationalkinhibitorscanadianrealworldexperience AT juergensrosalyna lorlatinibeffectivenessandqualityoflifeinpatientswithalkpositivensclcwhohadfailedsecondgenerationalkinhibitorscanadianrealworldexperience AT chuquincy lorlatinibeffectivenessandqualityoflifeinpatientswithalkpositivensclcwhohadfailedsecondgenerationalkinhibitorscanadianrealworldexperience AT blaisnormand lorlatinibeffectivenessandqualityoflifeinpatientswithalkpositivensclcwhohadfailedsecondgenerationalkinhibitorscanadianrealworldexperience AT banerjishantanu lorlatinibeffectivenessandqualityoflifeinpatientswithalkpositivensclcwhohadfailedsecondgenerationalkinhibitorscanadianrealworldexperience AT ngryan lorlatinibeffectivenessandqualityoflifeinpatientswithalkpositivensclcwhohadfailedsecondgenerationalkinhibitorscanadianrealworldexperience AT khoudigianshoghag lorlatinibeffectivenessandqualityoflifeinpatientswithalkpositivensclcwhohadfailedsecondgenerationalkinhibitorscanadianrealworldexperience AT sharmaarushi lorlatinibeffectivenessandqualityoflifeinpatientswithalkpositivensclcwhohadfailedsecondgenerationalkinhibitorscanadianrealworldexperience AT onphuvinh lorlatinibeffectivenessandqualityoflifeinpatientswithalkpositivensclcwhohadfailedsecondgenerationalkinhibitorscanadianrealworldexperience AT liugeoffrey lorlatinibeffectivenessandqualityoflifeinpatientswithalkpositivensclcwhohadfailedsecondgenerationalkinhibitorscanadianrealworldexperience |